GLUCOSE HEALTH, INC.

A NEVADA Corporation

609 SW 8th Street
Suite 600
Bentonville, AR 72712

Telephone: (479) 802-3827
Corporate Website: www.glucosehealthinc.com
Corporation Email: info@glucosehealthinc.com
SIC: 2833

ANNUAL REPORT

For the Period Ending: December 31, 2018
(the "Reporting Period")

As of December 31, 2018, the number of shares outstanding of our Common Stock was:

6,533,891

As of December 31, 2017, the number of shares outstanding of our Common Stock was:

4,971,895

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒ (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control[i] of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Glucose Health, Inc. *(f/k/a Bio-Solutions Corp. though November 19, 2014)*

Glucose Health, Inc. was incorporated under the laws of the State of Nevada on March 27, 2007, as Bio-Solutions Corporation. On November 19, 2014, we changed our name to Glucose Health, Inc. Our principal executive office is located at 609 SW 8th Street, Suite 600, Bentonville, AR 72712 and our telephone number is 479-802-3827. Our corporate website is www.glucosehealthinc.com, and our product website is www.glucodown.com.

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

2) Security Information

Trading symbol:	GLUC
Exact title and class of securities outstanding:	Common Stock
CUSIP:	379894108
Par or stated value:	$0.001
Total shares authorized:	200,000,000 as of date: December 31, 2018
Total shares outstanding:	6,533,891 as of date: December 31, 2018
Number of shares in the Public Float:	5,680,205 as of date: March 31, 2019
Total number of shareholders of record:	119 as of date: December 31, 2018

Additional class of securities (if any):

Trading symbol:	GLUC
Exact title and class of securities outstanding:	Preferred Stock
CUSIP:	379894108
Par or stated value:	No Par Value
Total shares authorized:	1,000 as of date: December 31, 2018
Total shares outstanding:	1,000 as of date: December 31, 2018

Transfer Agent

Name:	Nevada Agency & Transfer Company
Phone:	775-322-0626
Email:	info@natco.com

Is the Transfer Agent registered under the Exchange Act? Yes: ☒ No: ☐

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

3) Issuance History

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Number of Shares outstanding as of December 31, 2016	Opening Balance: Common: 3,312,273 Preferred: 1,000								
Date of Transaction	**Transaction type (e.g. new issuance, cancellation, shares returned to treasury)**	**Number of Shares Issued (or cancelled)**	**Class of Securities**	**Value of shares issued ($/per share) at Issuance**	**Were the shares issued at a discount to market price at the time of issuance? (Yes/No)**	**Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).**	**Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)**	**Restricted or Unrestricted as of this filing?**	**Exemption or Registration Type?**
March 7, 2017	New	111,214	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
April 3, 2017	New	162,500	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
May 5, 2017	New	176,938	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
May 30, 2017	New	2,072	Common Stock	3.25	No	Finch Capital Management Inc.**	Conversion of debt	Restricted	Section 3(a)(9) of Securities Act
May 30, 2017	New	1,983	Common Stock	3.25	No	Hanbury Ltd.**	Conversion of debt	Restricted	Section 3(a)(9) of Securities Act
May 30, 2017	New	2,072	Common Stock	3.25	No	Select Management Inc.**	Conversion of debt	Restricted	Section 3(a)(9) of Securities Act
June 12, 2017	New	25,000	Common Stock	0.0363	No	John Lykins	Services	Restricted	Sec 4(a)(2)
June 21, 2017	New	185,740	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
August 16, 2017	New	187,500	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
August 24, 2017	New	160,500	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
September 25, 2017	New	188,018	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
October 6, 2017	New	17,500	Common Stock	0.161	No	John Lykins	Services	Restricted	Sec 4(a)(2)
October 24, 2017	New	12,000	Common Stock	0.50	No	DMBM Inc.***	Conversion of debt	Restricted	Section 3(a)(9) of Securities Act
November 15, 2017	New	216,274	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
December 15, 2017	New	210,311	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
January 12, 2018	New	238,163	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act

March 1, 2018	New	246,563	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
March 20, 2018	New	259,512	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
April 1, 2018	New	231,281	Common Stock	0.015	Yes	NWBB Inc.****	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
May 1, 2018	New	276,028	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
October 30, 2018	New	310,449	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
January 11, 2019	New	320,394	Common Stock	0.008	Yes	Capital Consulting Inc.*	Conversion of debt	Unrestricted	Section 3(a)(9) & 4(a)(1) of Securities Act
February 22, 2019	New	50,000	Common Stock	0.045	Yes	Marion R. Jenkins	Services	Restricted	Sec 4(a)(2)
Shares Outstanding on December 31, 2018:	Ending Balance: Common: 6,533,891 Preferred: 1,000								

*Capital Consulting Inc. (Mark Schaftlein); **Select Management Inc., **Finch Capital Management Inc., **Hanbury Ltd. (Daniel Matsutono); ***DMBM Inc. (Damon Devitt); ***NWBB Inc. (Marc Hatch).

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures **in the past two completed fiscal years and any subsequent interim period**.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance ($)	Principal Amount at Issuance ($)	Interest Accrued ($)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)
November 22, 2017	60,000	60,000	-0-	None	None	Capital Consulting Inc.	Loan
November 28, 2017	25,000	25,000	3,247	December 31, 2019	None	BTB Management Inc./Murray Fleming, CEO/CFO	Loan
March 2018	20,000	20,000	1,821	December 31, 2019	None	BTB Management Inc./Murray Fleming, CEO/CFO	Loan
May 2018	36,000	36,000	2,687	December 31, 2019	None	BTB Management Inc./Murray Fleming, CEO/CFO	Loan
October 2018	15,000	15,000	365	December 31, 2019	None	BTB Management Inc./Murray Fleming, CEO/CFO	Loan
December 7, 2018	22,979	22,979	76	December 31, 2019	0.10	Capital Consulting Inc.	Loan*

*On December 7, 2018, the Company and Capital Consulting Inc. entered into a debt consolidation and modification agreement. The new agreement consolidated three loans and related accrued interest into a total amount due of $22,979. The new loan bears interest at 5% per annum, is due on demand and has a fixed conversion price of $0.10 per share. As of December 31, 2018, $22,979 remains outstanding.

4) Financial Statements

A. The following financial statements were prepared in accordance with:

☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual):

Name: **Judith Norstrud**
Title: **CPA, Consultant**
Relationship to Issuer: **Independent Consultant**

INDEX TO FINANCIAL STATEMENTS

GLUCOSE HEALTH, INC.
BALANCE SHEETS

ASSETS		December 31, 2018 (unaudited)		December 31, 2017 (unaudited)
CURRENT ASSETS				
Cash	$	20,304	$	22,406
Accounts receivable, net of allowance for doubtful accounts of $11,596 and $11,596, respectively		19,454		1,441
Inventory		57,621		2,904
Total current assets		97,379		26,751
Other Asset				
Intellectual assets, net of accumulated amortization of $180 and $120, respectively		120		180
TOTAL ASSETS	$	97,499	$	26,931
LIABILITIES AND STOCKHOLDERS' DEFICIT				
CURRENT LIABILITIES				
Accounts payable and accrued expenses	$	36,085	$	36,585
Accrued interest		59,094		49,176
Notes payable, related party		116,000		60,000
Notes payable		60,000		35,000
Convertible notes payable, related party		112,157		112,157
Convertible notes payable		169,159		156,070
Other notes payable		7,500		10,500
Total current liabilities		559,995		459,488
TOTAL LIABILITIES		559,995		459,488
COMMITMENT AND CONTINGENCIES				
STOCKHOLDERS' DEFICIT				
Preferred stock, no par value, 1,000 shares authorized, 1,000 shares issued and outstanding as of December 31, 2018 and 2017, respectively		113,200		113,200
Common stock, $0.001 par value, 200,000,000 shares authorized, 6,533,891 and 4,971,895 shares issued and outstanding as of December 31, 2018 and 2017, respectively		6,534		4,972
Additional paid in capital		5,740,207		5,724,655
Stock subscription		23,000		23,000
Accumulated other comprehensive loss		(75,278)		(75,278)
Accumulated deficit		(6,270,159)		(6,223,106)
Total stockholders' deficit		(462,496)		(432,557)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	97,499	$	26,931

The accompanying notes are an integral part of these financial statements.

GLUCOSE HEALTH INC.
STATEMENTS OF OPERATIONS
FOR THE YEAR'S ENDED DECEMBER 31,
(unaudited)

	2018	2017
REVENUE	$ 197,500	$ 104,522
COST OF REVENUES		
Cost of revenues	144,682	59,410
GROSS PROFIT	52,818	45,112
OPERATING EXPENSES		
Professional fees	38,939	58,906
General and administrative	37,365	46,047
Total Operating Expenses	76,304	104,953
INCOME (LOSS) FROM OPERATIONS	(23,486)	(59,841)
OTHER INCOME (EXPENSE)		
Interest income (expense)	(23,567)	(19,522)
Gain on forgiveness of accounts payable	-	103,894
Total other expense	(23,567)	84,372
INCOME (LOSS) BEFORE INCOME TAXES	(47,053)	24,531
PROVISION FOR (BENEFIT FROM) INCOME TAXES	-	-
NET INCOME (LOSS)	$ (47,053)	$ 24,531
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC AND DILUTED	6,022,480	3,976,277
NET INCOME (LOSS) PER SHARE - BASIC AND DILUTED	$ (0.01)	$ 0.01

The accompanying notes are an integral part of these financial statements.

GLUCOSE HEALTH, INC.
STATEMENT OF STOCKHOLDERS' DEFICIT

	Preferred Stock		Common Stock		Additional Paid-In	Stock To Be	Accumulated	Accumulated Other Comprehensive	
	Shares	Amount	Shares	Amount	Capital	Issued	Deficit	Loss	Total
Balance - December 31, 2014 (3)	1,000	$ 113,200	1,309,825	$ 1,310	$ 5,228,346	$ 23,000	$ (5,571,130)	$ (75,278)	$ (280,552)
Common stock issued in satisfaction of debt			58,092	58	232				290
Common stock issued in satisfaction of debt			58,750	59	235				294
Common stock issued in satisfaction of debt			59,078	59	236				295
Common stock issued in satisfaction of debt			59,244	59	237				296
Common stock issued in satisfaction of debt			54,018	54	216				270
Common stock issued as compensation			70,867	71	5,929				6,000
Common stock issued in satisfaction of debt			108,246	108	433				541
Common stock issued in satisfaction of debt			100,000	100	1,687				1,787
Common stock issued in satisfaction of debt			86,882	87	348				435
Common stock issued in satisfaction of debt			87,564	88	350				438
Common stock issued for sevices			10,000	10	490				500
Common stock issued for sevices			50,000	50	22,725				22,775
Common stock issued in satisfaction of debt			88,438	88	354				442
Common stock issued in satisfaction of debt			89,020	89	3,472				3,561
Balance - December 31, 2016 (3)	1,000	113,200	3,312,273	3,312	5,687,956	23,000	(6,247,637)	(75,278)	(495,447)
Common stock issued in satisfaction of debt (unaudited)			1,617,122	1,617	33,018				34,635
Common stock issued for services (unaudited)			42,500	43	3,681				3,724
Net income (unaudited)							24,531		24,531
Balance - December 31, 2017 (unaudited)	1,000	113,200	4,971,895	4,972	5,724,655	23,000	(6,223,106)	(75,278)	(432,557)
Common stock issued in satisfaction of debt (unaudited)			1,561,996	1,562	12,552				14,114
Beneficial conversion feature (unaudited)					3,000				3,000
Net loss (unaudited)							(47,053)		(47,053)
Balance -December 31, 2018 (unaudited)	1,000	113,200	6,533,891	6,534	5,740,207	23,000	(6,270,159)	(75,278)	(462,496)

(3) The common stock shares authorized, issued and outstanding have been adjusted to reflect a 10 to 1 reverse split, which was effective in February 2014 and 50 to 1 reverse split, which was effective in November 2014

GLUCOSE HEALTH, INC.
STATEMENTS OF CASH FLOWS
(unaudited)

	FOR THE YEAR'S ENDED DECEMBER 31, 2018	2017
OPERATING ACTIVITIES:		
Net (loss) income	$ (47,053)	$ 24,531
Adjustments to reconcile net loss to net cash used in operating activities:		
Common stock issued for services	-	3,724
Amortization of intangible asset	60	60
Beneficial conversion feature	3,000	-
Bad debt expense	-	14,746
Gain on settlement of accounts payable	-	(103,894)
Change in assets and liabilities		
(Increase) decrease in accounts receivable	(18,013)	(4,463)
Decrease (increase) in inventory	(35,169)	(2,904)
(Increase) decrease in prepaid expenses and other current assets	-	639
Increase (decrease) in accounts payable and accrued expenses	6,823	9,425
Total adjustments	(43,299)	(82,667)
Net cash used in operating activities	(90,352)	(58,136)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Net cash used in investing activities	-	-
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from notes and loans payable	117,000	83,500
Payments on notes and loans payable	(28,750)	(23,500)
Net cash provided by financing activities	88,250	60,000
NET DECREASE IN CASH	(2,102)	1,864
CASH - BEGINNING OF YEAR	22,406	20,542
CASH - END OF YEAR	$ 20,304	$ 22,406
NONCASH OPERATING AND INVESTING ACTIVITIES:		
Conversion of notes payable and accrued interest to common stock	$ 14,115	$ 34,635

The accompanying notes are an integral part of these financial statements.

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

We were incorporated under the laws of State of Nevada on March 27, 2007, as Bio-Solutions Corp. On November 19, 2014, we changed our name to Glucose Health, Inc. to reflect our current business. Our authorized common shares are 200,000,000 and authorized Series A preferred shares are 1,000. As of December 31, 2018, 6,533,891 of the Company's common stock and 1,000 shares of the Company's preferred stock were issued and outstanding. Our business is the manufacturing and sales of GLUCODOWN® branded dietary supplement products.

Basis of Presentation

The accompanying unaudited condensed interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements.

In the opinion of management, the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, bad debts, investments, intangible assets, and income taxes. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Comprehensive Income (Loss)

The Company adopted ASC 220-10, "Reporting Comprehensive Income." ASC 220-10 requires the reporting of comprehensive income in addition to net income from operations. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.

Cash Flow Reporting

The Company follows ASC 230, Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method ("indirect method") as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. There were no cash equivalents as of December 31, 2018 and 2017.

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.

Accounts Receivable

Accounts receivable consists of invoiced and unpaid product sales. The Company records an allowance for doubtful accounts to allow for any amounts that may not be recoverable, which is based on an analysis of the Company's prior collection experience, customer credit worthiness, and current economic trends. During the year's ended December 31, 2018 and 2017, we recorded $11,596 of allowance for doubtful accounts based upon management's review of accounts receivable.

On October 4, 2016, the Company executed a non-recourse receivables financing agreement with Citibank whereby receivables due to the Company are assumed from a large customer by Citibank and paid to the Company in a shorter period than otherwise provided for in accordance with the supplier agreement with the large customer, subject to a fixed interest premium based upon LIBOR.

Prepaid Expenses

The Company considers all items incurred for future services to be prepaid expenses. As of December 31, 2018, and 2017 the Company had no prepaid expenses.

Recoverability of Long-Lived Assets

The Company reviews its long-lived assets on a periodic basis, namely intellectual property, whenever events and changes in circumstances have occurred which may indicate a possible impairment. The assessment for potential impairment will be based primarily on the Company's ability to recover the carrying value of its long-lived assets from expected future cash flows from its operations on an undiscounted basis. If such assets are determined to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Fixed assets to be disposed of by sale will be carried at the lower of the then current carrying value or fair value less estimated costs to sell.

The Company evaluates the carrying value of goodwill during the fourth quarter of each year and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating whether goodwill is impaired, the Company compares the fair value of the reporting unit to which the goodwill is assigned to the reporting unit's carrying amount, including goodwill. The fair value of the reporting unit is estimated using a combination of the income, or discounted cash flows, approach and the market approach, which utilizes comparable companies' data. If the carrying amount of a reporting unit exceeds its fair value, then the amount of the impairment loss must be measured. The impairment loss would be calculated by comparing the implied fair value of reporting unit goodwill to its carrying amount. In calculating the implied fair value of reporting unit goodwill, the fair value of the reporting unit is allocated to all the other assets and liabilities of that unit based on their fair values. The excess of the fair value of a reporting unit over the amount assigned to its other assets and liabilities, is the implied fair value of goodwill.

We make critical assumptions and estimates in completing impairment assessments of goodwill and other intangible assets. Our cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, market competition, inflation and discount rates. A 10% decrease in the estimated discounted cash flows for the reporting units tested would result in impairment that is not material to our results of operations. A 1.0 percentage point increase in the discount rate used would also result in impairment that is not material to our results of operations.

We amortize the cost of other intangible assets over their estimated useful lives, which range up to ten years, unless such lives are deemed indefinite. Intangible assets with indefinite lives are tested in the third quarter of each fiscal year for impairment, or more often if indicators warrant.

During the year's ended December 31, 2018 and 2017, we recorded no impairment charges related to other intangible assets.

Fair Value of Financial Instruments

The carrying amount reported in the balance sheets for cash, accounts payable, accrued expenses, and short-term notes approximate fair value because of the immediate or short-term maturity of these financial instruments. The Company does not utilize derivative instruments.

ASC 820, *Fair Value Measurements and Disclosures*, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities

Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2018. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

Beneficial Conversion Features

ASC 470-20 applies to convertible securities with beneficial conversion features that must be settled in stock and to those that give the issuer a choice in settling the obligation in either stock or cash. ASC 470-20 requires that the beneficial conversion feature should be valued at the commitment date as the difference between the conversion price and the fair market value of the common stock into which the security is convertible, multiplied by the number of shares into which the security is convertible. This amount is recorded as a debt discount and amortized over the life of the debt. ASC 470-20 further limits this amount to the proceeds allocated to the convertible instrument.

Income Taxes

The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.

The Company follows ASC 740-10, "Accounting for Uncertainty in Income Taxes" ("ASC 740-10"). This interpretation requires recognition and measurement of uncertain income tax positions using a "more-likely-than-not" approach. The Company has adopted ASC 740-10 for 2016, and evaluates its tax positions on an annual basis, and as of December 31, 2018, no additional accrual for income taxes is necessary. The Company's policy is to recognize both interest and penalties related to unrecognized tax benefits expected to result in payment of cash within one year are classified as accrued liabilities, while those expected beyond one year are classified as other liabilities. The Company has not recorded any interest or penalties since its inception. The Company is required to file income tax returns in the U.S. federal tax jurisdiction and in various state tax jurisdictions and the prior three fiscal years remain open for examination by federal and/or state tax jurisdictions. The Company is currently not under examination by any other tax jurisdictions for any tax year.

Revenue Recognition

In accordance with Securities and Exchange Commission Staff Accounting Bulletin (SAB) No. 104, *Revenue Recognition*, (codified in ASC 605) the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists or acceptance occurs, (ii) a retailer, distributor or wholesaler receives the goods, (iii) the price is fixed or determinable, and (iv) collectability of the sales revenues is reasonably assured.

Share Based Compensation

The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 718 and No. 505. The Company issues restricted stock to employees for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company also issues restricted stock to consultants for various services. Costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment only if there is sufficient disincentive to ensure performance or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.

(Loss) Income Per Share of Common Stock

Basic net loss/income per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. Except as noted below, the Company has not issued any options or warrants to date. At December 31, 2018, the total shares issuable upon conversion of all convertible notes payable would be 33,243,228 shares of the Company's common stock. All convertible notes payable provide for a beneficial ownership limitation of 4.99%.

Inventory

Inventory is stated at the lower of cost (FIFO: first-in, first-out) or market, and includes finished goods and raw materials. The cost of finished goods includes the cost of packaging supplies, direct and indirect labor and other indirect manufacturing costs. As of December 31, 2018, the Company had raw materials inventory of $24,093 and finished goods of $33,528, with no allowance for obsolescence.

Recently Issued Accounting Standards Not Yet Adopted

None.

NOTE 3 – STOCKHOLDERS' DEFICIT

Our current authorized common shares are 200,000,000 and 1,000 preferred voting shares. As of December 31, 2018, 6,533,891 of the Company's common stock and 1,000 shares of the Company's Series A preferred stock were issued and outstanding.

Issuances pursuant to conversions

During March 2017, the Company issued 111,214 unregistered shares of common stock to a corporation for conversion of $850 principal and $40 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During April 2017, the Company issued 162,500 unregistered shares of common stock to a corporation for conversion of $1,300 of accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During May 2017, the Company issued 176,938 unregistered shares of common stock to a corporation for conversion of $600 principal and $816 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During May 2017, the Company issued 6,127 unregistered shares of common stock to three corporations for a mandatory conversion of $19,222 principal and $689 accrued interest related to three individual notes. These unregistered shares were valued at $3.25 per share, the fixed conversion price stated in the note, as adjusted for the two stock splits that occurred between the mandatory conversion date and the issuance of the common stock.

During June 2017, the Company issued 185,740 unregistered shares of common stock to a corporation for conversion of $1,400 principal and $86 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During August 2017, the Company issued 187,500 unregistered shares of common stock to a corporation for conversion of $1,500 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During August 2017, the Company issued 160,500 unregistered shares of common stock to a corporation for conversion of $1,200 principal and $84 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During September 2017, the Company issued 188,018 unregistered shares of common stock to a corporation for conversion of $1,400 principal and $104 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During October 2017, the Company issued 12,000 unregistered shares of common stock to an individual in conversion of a $6,000 outstanding balance related to a note issued January 25, 2013, in accordance with a contractual agreement and retired the note. These unregistered shares were valued at 0.1609 per share, the closing price on October 20, 2017, however, the original conversion price was $0.001.

During November 2017, the Company issued 216,274 unregistered shares of common stock to a corporation for conversion of $1,600 principal and $130 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During December 2017, the Company issued 210,311 unregistered shares of common stock to a corporation for conversion of $1,550 principal and $132 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During January 2018, the Company issued 238,163 unregistered shares of common stock to a corporation for conversion of $1,750 principal and $155 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During March 2018, the Company issued 246,563 unregistered shares of common stock to a corporation for conversion of $1,800 principal and $173 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During March 2018, the Company issued 259,512 unregistered shares of common stock to a corporation for conversion of $1,890 principal and $186 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During May 2018, the Company issued 276,028 unregistered shares of Common Stock to a corporation for conversion of $2,000 principal and $208 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During May 2018, the Company issued 231,281 unregistered shares of Common Stock to a corporation for conversion of $3,000 principal and $469 accrued interest related to a note. These unregistered shares were valued at $0.015 per share, the fixed conversion price stated in the note.

During October 2018, the Company issued 310,449 unregistered shares of Common Stock to a corporation for conversion of $2,200 principal and $284 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

Issuances pursuant to agreements

During October 2017, the Company issued 17,500 shares of unregistered common stock to an individual. The unregistered common stock was valued at $2,818.

NOTE 4 – NOTES PAYABLE

Notes payable, related party:

On May 1, 2016, the Company issued a $35,000 note to a corporation owned by the Company's CEO. The loan bears interest at 24% per annum and has a maturity date of December 31, 2016. $20,000 remains outstanding as of December 31, 2018.

On November 28, 2017, the Company issued a $25,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of March 28, 2018. As of December 31, 2018, $25,000 remains outstanding.

During March 2018, the Company issued a $20,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of July 27, 2018. As of December 31, 2018, $20,000 remains outstanding.

During May 2018, the Company issued a $36,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of September 15, 2018. As of December 31, 2018, $36,000 remains outstanding.

During October 2018, the Company issued a $15,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of February 15, 2019. As of December 31, 2018, $15,000 remains outstanding.

Notes payable:

On May 15, 2017, the Company issued an $18,000 note to a corporation. The loan bears interest at 12% per annum and is payable on demand. As of December 31, 2018, $10,000 remains outstanding.*

On November 22, 2017, the Company signed a $60,000 revolving line of credit agreement with a corporation. The outstanding balance bears simple interest of 10% per annum, payable monthly in arrears. As of December 31, 2018, $60,000 is outstanding.

Convertible notes payable, related party

The Company consolidated 18 separate convertible promissory notes of various principal amounts and fixed conversion prices, all bearing 5% interest per annum, issued to a corporation owned by the Company's CEO during the period from August 4, 2014 through April 1, 2016, into a single convertible promissory note of $112,157, bearing 5% interest per annum with a pro-rata fixed conversion price of $0.011, plus $5,939 accrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation owned by the Company's CEO. The current net note balance is $112,157.

Convertible notes payable:

The Company consolidated 20 separate convertible promissory notes of various principal amounts and fixed conversion prices, all bearing 5% interest per annum, issued to corporation during the period from August 2, 2013 through April 1, 2016, into a single convertible promissory note of $169,065, bearing 5% interest per annum with a pro-rata fixed conversion price of $0.008, plus $12,516 accrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation. The current note balance is $146,180.

On June 7, 2018, the Company issued a $6,000 convertible note to a corporation. The loan bears interest at 5% per annum, has a fixed conversion price of $0.05 and a maturity date of December 31, 2018. $6,000 remains outstanding at December 31, 2018.*

On November 19, 2018, the Company issued a $5,000 convertible note to a corporation. The loan bears interest at 5% per annum, has a fixed conversion price of $0.05 and is due on demand. $5,000 remains outstanding at December 31, 2018.*

*On December 7, 2018, the Company and the corporation entered into a debt consolidation and modification agreement for the above noted loans. The new agreement consolidated the three loans and related accrued interest into a total amount due of $22,979, bears interest at 5% per annum, due on demand and has a fixed conversion price of $0.10 per share. As of December 31, 2018, $22,979 remains outstanding.

Other notes payable:

On December 10, 2013, the Company issued a $3,000 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.015 and a maturity date of June 10, 2014. $3,000 remains outstanding at December 31, 2018.

On December 10, 2013, the Company issued a $5,000 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.015 and a maturity date of June 10, 2014. $2,000 remains outstanding at December 31, 2018.

On April 20, 2012, the Company issued a $2,500 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.009 and a maturity date of October 20, 2012. $2,500 remains outstanding at December 31, 2018.

Accrued Interest

At December 31, 2018, accrued interest on all notes and convertible notes amounted to $59,094.

NOTE 5 – INTELLECTUAL PROPERTY

On October 1, 2014, the Company entered into an Intellectual Property Purchase Agreement to purchase “Glucose Health” for the purchase price of 300,000 unregistered shares of the Company’s common stock from a company beneficially owned by the Company’s CEO, Murray Fleming. The shares were recorded at their par value of $0.001 per share or $300, valued at the nominal historical cost of the related party seller. All assets other than the intellectual property had a fair value of $0, with the intellectual property valued at $300 net of $180 of accumulated amortization.

NOTE 6 – COMMITMENTS/CONTINGENCIES

From time to time, we may be involved in litigation in the ordinary course of business. We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations.

Operating Agreements

On January 8, 2016, we entered into a supplier agreement with a national retailer customer.

On January 25, 2016, we entered into an agreement for manufacturing services with Natural Solution Labs of Gravette, AR.

On April 12, 2016, we entered into an agreement for warehousing, logistics and fulfillment services NWA Logistics of Rogers, AR.

On November 27, 2017 we entered into an agreement for manufacturing services with Zumbro River Brands of Albert Lea, MN.

On February 5, 2018, we entered into a Commercial General Liability insurance policy underwritten by Lloyd’s of London represented by Citadel Insurance Services.

NOTE 7 – MAJOR CUSTOMERS and ACCOUNTS RECEIVABLE

The Company has a one customer whose revenue individually represents more than 10% of the Company’s total revenues and one customer whose accounts receivable represents more than 10% of the Company’s accounts receivable. The Company expects to maintain this relationship and has assessed the credit worthiness of this customer and does not currently believe an allowance for accounts receivable impairment is required.

NOTE 8 – SUBSEQUENT EVENTS

During January 2018, the Company issued 320,394 unregistered shares of Common Stock to a corporation for conversion of $2,250 principal and $313 of accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During February 2019, the Company issued 50,000 shares of unregistered common stock to an individual for services rendered. The unregistered common stock was valued at $2,252, which represents 50% of the closing stock price of $0.091.

5) Issuer's Business, Products and Services

A. Summary of the issuer's business operations:

We are a manufacturer of dietary supplements marketed under the GLUCODOWN® brand, serving the over-the-counter, diabetic nutritionals, consumer market segment. Our Standard Industrial Classification (SIC) code is 2833 (Medicinal Chemicals and Botanical Products). As discussed in greater detail below, we are in the early stages of developing, manufacturing, marketing and distributing our dietary supplement products.

B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

None

C. Describe the issuers' principal products or services, and their markets

Glucose Health, Inc. manufacturers and distributes dietary supplements under the GLUCODOWN® brand. Our dietary supplements are formulated with ingredients demonstrated in certain clinical research, such as published on the National Institutes of Health, National Library of Medicine website (see www.glucodown.com/clinical-trials), to have a beneficial impact upon blood glucose, triglyceride and cholesterol levels and digestive health. The Centers for Disease Control and Prevention (CDC) publishes a National Diabetes Statistics Report annually. The 2014 Report estimates 2 of 5 presently healthy Americans will develop Type-2 diabetes in their lifetime. We believe the CDC Report and other similar research points to a large and growing market of consumers likely concerned with pre-diabetes or Type-2 diabetes, including many of whom are also likely purchasers of dietary supplements. While our primary focus is growing our sales to these consumers through national and regional pharmacy chain retailers, secondarily, we also market GLUCODOWN® to these customers via selected online marketplaces.

On October 1, 2014, the Company entered into an agreement to acquire the "Glucose Health" intellectual property from a corporation beneficially owned by the Company's CEO.

Beginning in October 2014, we undertook a series of steps to achieve commercialization of a "Glucose Health" dietary supplement product that would be considered both efficacious and pleasant tasting by our target consumer market, being persons concerned with pre-diabetes and Type-2 diabetes; and further would offer a value proposition, relative to our competition, to be favorably considered by national and regional pharmacy chain retailer buyers for inclusion on their store shelves. This series of steps included retaining a former head of beverage product development at Nestle to refine our product formula; retaining an attorney specializing in Food and Drug Administration (FDA) and Federal Trade Commission (FTC) regulations pertaining to dietary supplements to establish and ensure our compliance with such regulations; conducting an international graphic design competition for branding Glucose Health; retaining an experienced graphic artist specializing in consumer product packaging to create all digital and print representations of Glucose Health; and filing and being granted trademark protection for Glucose Health® with the United States Trademark and Patent Office (USPTO).

On November 19, 2014, we changed our name from Bio-Solutions Inc. to Glucose Health, Inc. to reflect our new business operations.

On January 5, 2015, we signed a contract manufacturing agreement for testing, compounding, supply and order fulfillment for the first iteration of the Glucose Health product and additionally a purchasing agreement to distribute the first iteration of the product through a limited number of Northwest Arkansas pharmacies.

On January 7, 2015, we completed implementation of Current Good Manufacturing Practices (CGMP). The Dietary Supplement (DS) CGMP rule in 21 CFR part 111 of the FDA's regulations requires companies which manufacture, package, label, or hold a dietary supplement to establish and follow current good manufacturing practice to ensure the quality of the dietary supplement and to ensure that the dietary supplement is packaged and labeled as specified in the master manufacturing record.

On January 26, 2015, we filed an initial application for trademark protection related to its line of dietary supplement products, with the United States Trademark and Patent Office (USPTO).

On January 29, 2015, we appointed Chandrasekhar Mallangi, Ph.D., as an advisor. Dr. Mallangi earned a Ph.D. in Food Science from Oregon State University and is an advisor to multinational companies in the development of nutritional products. Dr. Mallangi is the credited inventor and co-inventor for patents awarded by the USPTO to subsidiaries of Nestle, SA of Vevey, Switzerland.

On February 10, 2015, Murray Fleming, our Chief Executive Officer was appointed our Chief Financial Officer.

On February 24, 2015, we completed FDA facility registration, a compliance procedure for manufacturers of dietary supplements.

On May 26, 2015, we completed the first production run of the first iteration of Glucose Health and pursuant to the January 5, 2015 purchasing agreement, Glucose Health began to be offered for retail sale through a limited number of Northwest Arkansas pharmacies as well as on our product website www.glucodown.com.

On July 7, 2015, we received notification from the United States Patent and Trademark Office (USPTO) that its application for trademark of “Glucose Health” was accepted to the Supplemental Register (Reg. 4770720) with first use recognized by the USPTO as of February 1, 2015.

On January 6, 2016, we executed a supplier agreement with a large national pharmacy retailer.

On February 4, 2016, our Chief Executive Officer and Chief Financial Officer, Murray Fleming, was appointed to our board of directors.

On March 8, 2016, we received a series of material purchase orders from a large national pharmacy retailer pursuant to a material supplier agreement.

On October 4, 2016, we executed a non-recourse receivables financing agreement with Citibank, N.A. (Citibank) whereby receivables are paid to us by Citibank for a large pharmacy retailer customer, subject to an interest premium.

In April 2017, we undertook a series of steps to achieve production of a new and improved, second iteration, dietary supplement product. This series of steps included improving the nutritional formula with the addition of 6 targeted vitamins and minerals and the natural plant extract Banaba Leaf; implementation of an additional manufacturing process to agglomerate the product formula to improve solubility; sourcing natural flavors from an industry leading flavoring house; and improving product directions and packaging information based upon consumer feedback from the first iteration product.

On May 29, 2018, we received notification from the United States Patent and Trademark Office (USPTO) that our application for the trademark of “GLUCODOWN” was accepted to the Principal Register (Reg. 87673071) with first use pending.

In June 2018, we introduced new GLUCODOWN® Diabetic Friendly Formula Tea Mix in Peach, Lemon, Raspberry and Super Berry flavors. We are engaged in active development of additional products and line extensions targeting our market niche.

As of December 31, 2018, GLUCODOWN® dietary supplements are stocked by pharmacy chain retailers in all 50 states and are additionally available for purchase in selected online marketplaces.

Competition

The business of developing and distributing dietary supplements is highly competitive. Our product has direct and indirect competition. We compete with Glucerna® Advance, manufactured by Abbott Laboratories; Boost® Glucose Control, manufactured by Nestle; and Enterex® Diabetic, manufactured by Victus, Inc. All the companies whom are our direct competitors are substantially larger with much greater financial resources and broader name recognition. Although we are a small company, we believe we have a competitive advantage over our larger competitors because our GLUCODOWN® products are specifically formulated for persons concerned with pre-diabetes, Type-2 diabetes and digestive health. For example, our GLUCODOWN® branded products include soluble fiber, plant-based extracts and various micronutrients; each of which have been demonstrated in certain clinical studies to have beneficial impacts with respect to blood glucose, triglycerides, cholesterol and digestive health. We also compete with Metamucil manufactured by Procter and Gamble and with the many dietary supplements marketed in capsule or tablet form to the pre-diabetic, Type-2 diabetic and digestive health, consumer market segments. There can be no assurance that we will be able to effectively compete in such a competitive environment.

Government Regulation

The manufacturing, processing, formulating, packaging, labeling, distributing, selling and advertising of our products are subject to government regulation, principally by the Food and Drug Administration (hereinafter the "FDA"). In particular, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements. The FDA permits "statements of nutritional support" for dietary supplements without FDA pre-approval. Such statements may describe how particular dietary ingredients affect the structure, function or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function or well-being (but may not state that a dietary supplement will diagnose, mitigate, treat, cure or prevent a disease). A company making a statement of nutritional support must possess substantiating evidence for the statement, and, for such statements that are not about the effects on the body because of a dietary supplement used as a tool for its nutritive value and are not otherwise "health claims," disclose on the label that the FDA has not reviewed that statement and that the product is not intended for use for a disease. Failure to comply with applicable FDA requirements can result in various levels of regulatory actions being imposed on the Company including but not limited to action letters, product recalls and injunctions.

In addition to the FDA, the Federal Trade Commission (hereinafter the "FTC") has additional jurisdiction to regulate the labeling, promotion and advertising of dietary supplements. The FTC is authorized to use a variety of processes and remedies for enforcement, both administratively and judicially, including compulsory process, cease and desist orders, and injunctions. FTC enforcement can result in orders requiring, among other things, limits on advertising, corrective advertising, consumer redress, divestiture of assets, rescission of contracts and such other relief as may be deemed necessary. State and local authorities can also regulate advertising and labeling for dietary supplements and conventional foods. Additionally, there can be no assurance that state and local authorities will not commence other regulatory actions that could restrict the permissible scope of our product claims.

6) Issuer's Facilities

Our principal office is located at 609 SW 8th Street, Suite 600, Bentonville, AR 72712, which we rent monthly. We additionally contract for product manufacturing at facilities located in Gravette, Arkansas and Albert Lea, Minnesota and logistics and fulfillment services at a facility in Rogers, Arkansas. We do not believe we will have difficulty in obtaining additional executive office, industrial manufacturing or commercial logistics space, at competitive prices, if necessary. We hold no real property.

7) Officers, Directors, and Control Persons

Using the tabular format below, please provide information regarding any person or entity owning 5% of more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City/State)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Murray Fleming	Officer, Director, 5%+ Owner.	N/A	600,000	Common Stock	9%	Chief Executive Officer, Chief Financial Officer & Sole Director
Murray Fleming	Officer, Director, 5%+ Owner.	N/A	1,000	Preferred Stock	100%	Chief Executive Officer, Chief Financial Officer & Sole Director

8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name:	Aaron McGeary
Firm:	The McGeary Law Firm PC
Address 1:	1600 Airport Fwy, Suite 300
Address 2:	Bedford, TX 76022
Phone:	817-282-5885

Accountant or Auditor

Name:	Judith Norstrud
Firm:	Norco Accounting & Consulting, Inc.
Address 1:	15837 Trackside Drive
Address 2:	Odessa, FL 33556
Phone:	813-205-4941

Investor Relations Consultant

None

Other Service Providers

None

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Murray Fleming certify that:

1. I have reviewed this annual disclosure statement of Glucose Health, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 1, 2019 [Date]

/s/ Murray Fleming [CEO's Signature]

Principal Financial Officer:

I, Murray Fleming certify that:

1. I have reviewed this annual disclosure statement of Glucose Health, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 1, 2019 [Date]

/s/ Murray Fleming [CFO's Signature]